TABLE 6.
Univariate and multivariate analysis of prognostic factors for PFS in patients with CSCC in the validation cohort.
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| p | HR (95% CI) | p | HR (95% CI) | |
| Age (≤45 vs. >45 years) | 0.090 | 0.358 (0.109–1.175) | ||
| FIGO stage (IB2-IIA2 vs. IIB) | 0.203 | 2.370 (0.629–8.937) | 0.201 | 2.623 (0.598–11.495) |
| Histological grade (G1-G2 vs. G3) | 0.562 | 0.704 (0.215–2.306) | 0.847 | 0.884 (0.251–3.790) |
| Tumor size (≤5 vs. >5 cm) | 0.197 | 2.184 (0.666–7.160) | 0.227 | 2.120 (0.627–7.164) |
| Tumor growth pattern (exogenous vs. endogenous) | 0.616 | 1.693 (0.216–13.254) | ||
| NACT cycles (≤2 vs. >2) | 0.560 | 1.424 (0.434–4.667) | 0.985 | 1.013 (0.271–3.790) |
| Adjuvant treatment (yes vs. no) | 0.643 | 0.615 (0.079–4.803) | ||
| SII (≤600.5683 vs. >600.5683) | 0.030 | 4.331 (1.148–16.334) | 0.038 | 4.090 (1.077–15.526) |
| PNI (≤49.5 vs. >49.5) | 0.673 | 1.331 (0.353–5.020) | ||
| PLR (≤153.4314 vs. >153.4314) | 0.674 | 1.291 (0.394–4.231) | ||
| LMR (≤12.25 vs. >12.25) | 0.787 | 0.049 (0- >1) | ||
| Neutrophil (≤5.35 vs. >5.35) | 0.154 | 2.443 (0.715–8.351) | ||
| Lymphocyte (≤0.87 vs. >0.87) | — | — | ||
| Platelet (≤216 vs. >216) | 0.649 | 1.612 (0.206–12.604) | ||
CSCC, cervical squamous cell carcinoma; PFS, progression free survival; HR, hazard ratio; CI, confidence interval; NACT, neoadjuvant chemotherapy; SII, systemic immune-inflammation index; PNI, prognostic nutritional index; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.